Arq (ARQ) Q3 2026 Earnings Call Transcript

Arq reported Q3 2026 revenue of $38.2 million, up 9% year over year; gross margin rose 1,100 bps to 39.7%, adjusted EBITDA increased 71% to $8.8 million, and net income was $2.5 million versus a $0.9 million loss a year earlier. The company tightened full-year 2026 adjusted EBITDA guidance to $19 million–$20 million from $17 million–$20 million, while reiterating revenue guidance of $120 million–$125 million. Management expects PAC for PFAS to contribute to growth in 2027, citing more than a dozen customer testing opportunities and an estimated 160 million pounds per year of addressable market by 2029; it also targets a roughly $30 million 2027 adjusted EBITDA exit run rate, excluding GAC-related growth and CapEx.

Analysis

The near-term investment case is operating leverage in the existing PAC franchise; the PFAS opportunity is an unproven call option, not yet a basis for underwriting the company’s 2027 target. The market-size estimate matters less than conversion: paid trials must become repeat orders at premium pricing, with efficacy demonstrated across customer-specific water conditions. PAC used ahead of GAC could also reduce GAC change-outs—supporting adoption as a complement, while potentially delaying some GAC purchases. That widens the use case but may temper demand for GAC suppliers and equipment providers.

The key quality check is whether recent margin strength persists beyond a seasonally strong quarter. Lower prior-year R&D comparability and higher incentive/professional costs complicate extrapolation; watch sequential gross margin, core PAC pricing/volume, and cash conversion rather than annualizing the quarter. Liquidity remains a meaningful counterweight: unrestricted cash is a fraction of total debt, and refinancing is an objective, not a completed transaction. Corbin proceeds and cost savings should not be capitalized into the thesis before execution.

Over 1–3 months, trial completion and early 2027 guidance are the catalysts. Over 6–18 months, repeat PFAS orders, refinancing terms, and operational throughput determine whether the earnings ramp is durable. The contrarian point: investors may over-focus on the large addressable-market estimate while underweighting capacity allocation, product qualification, and financing risk. Regulatory delay or reversal, weak trial conversion, or PAC margins reverting after seasonal volume would undermine the setup.

Key Decisions for Investors

• Treat ARQ as a high-risk, execution-dependent long rather than buying the PFAS market-size narrative outright. Consider staged exposure only after evidence of trial-to-contract conversion and repeat orders; keep sizing conservative given liquidity and refinancing dependence.
• Use early-2027 guidance as the next underwriting checkpoint. Require explicit PAC-for-PFAS volume, pricing, and ramp assumptions before assigning value to management’s 2027 exit-run-rate target.
• Monitor unrestricted cash, working-capital conversion, and refinancing progress over the next six months. A completed facility with improved liquidity would reduce balance-sheet risk; delay or restrictive terms would weaken the long thesis.
• Falsify the operating thesis if core PAC gross margin and cash generation retreat materially outside seasonal strength, or if customer trials fail to convert into paid recurring business. Regulatory changes that defer utility action are an additional downside catalyst.